Back to search

Article

Omicron variant escapes therapeutic mAbs contrary to eight prior main VOC

2022-01-03

Abstract excerpt

Monocolonal antibodies (mAbs) are currently used for active immunization of COVID-19 in immunocompromised patients. We herein show that in spite there are variations in susceptibility to available mAbs that are authorized for clinical use in France tested on the original B.1.1 virus and 9 variants of concern or of interest, the cocktail casirivimab/imdevimab (REGN-CoV-2) showed a major synergistic effect. However,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8e9eb39b-c03c-55c1-a724-a7c6534f1e26
DOI
10.1101/2022.01.03.474769
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Omicron variant escapes therapeutic mAbs contrary to eight prior main VOCDOI 10.1101/2022.01.03.474769
Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron Variant of ConcernSemantic proximity
Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individualsSemantic proximity
Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxisSemantic proximity
In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1Semantic proximity
Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variantsSemantic proximity
Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatmentSemantic proximity
Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5Semantic proximity
Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment.Semantic proximity
Evaluation of neutralizing capacity of tixagevimab plus cilgavimab: a case-series study with comparison to a vaccinated populationSemantic proximity
Convalescent plasma therapy in immunocompromised patients infected with the BA.1 or BA.2 Omicron SARS-CoV-2Semantic proximity
Neutralization of recent SARS-CoV-2 variants by genetically and structurally related mAbs of the pemivibart lineageSemantic proximity
Omicron variant evolution on vaccines and monoclonal antibodiesSemantic proximity
Select a neighboring publication to make it the new centre.